Skip to main content
Copenhagen-based Aisel Health raises €1.7 million to expand its AI platform for psychiatric care

Copenhagen-based Aisel Health raises €1.7 million to expand its AI platform for psychiatric care

Published: Aug 19, 2026, 01:20 PM EDT
Updated: Aug 19, 2026, 01:20 PM EDT

Copenhagen-based HealthTech company Aisel Health has raised €1.7 million in a pre-Seed funding round. The company is developing an operating system (OS) designed specifically for psychiatry and mental health care.

The funding round was led by Caesar Ventures, with participation from Nordic Web Ventures, LifeX and Angel Invest. Existing investors Rockstart and EIFO also joined the round.

“Psychiatry doesn’t need more generic technology bolted onto an already overburdened workflow. It needs a product built around the realities of psychiatric care – where clinicians bring judgment, empathy, and years of trained intuition, and the technology brings the speed, structure, and ability to hold together every detail about every patient, in a way no human memory can,” said Augusta Klingsten Peytz, co-founder and CEO of Aisel Health. 

Founded in 2024 by Peytz and Christian Houen, Aisel Health develops software to help psychiatric clinics manage their operations more efficiently. Its platform helps clinicians find the right patient information at the right time. The company says this can improve the patient experience, reduce workload for staff, and help clinics become more profitable.

Aisel Health says AI note-taking tools have made it easier and faster for clinicians to write patient notes. However, this has created another challenge: as more notes are produced, finding important information in patient records can become more difficult.

Patient information is often stored across different systems and collected over many years. As a result, clinicians can spend more time searching for relevant information than writing the actual notes.

According to Aisel Health’s latest research, “The Documentation Minute,” psychiatrists spend significantly more time gathering information than documenting it. Before assessing or treating a patient, they often need to review medical history from referrals, previous notes, and multiple systems.

“AI scribes work – they write notes faster, and that’s great for immediate burnout. But that’s not what’s keeping waiting lists long. Make notes cheaper to produce, and you just make that information harder to find when a clinician needs it. We still have yet to overcome the human limitation of understanding everything that was ever written about every patient ever treated – that’s the problem we built Aisel to solve: giving clinicians exactly what they need, when and how they need it,” said Christian Houen, co-founder and CPO of Aisel Health. 

Aisel Health says its platform helps reduce the paperwork burden for psychiatrists by quickly providing the patient history and clinical information they need. It combines interview recordings, existing documents, and information shared by patients to create structured and relevant insights for clinicians.

The platform supports psychiatrists before, during, and after consultations by giving them access to the patient’s documentation and important clinical context in one place.

Aisel Health also highlights its focus on security and data privacy. The company says it does not access patients’ medical records and does not use patient data to train its AI models. All data is stored and processed on secure servers in Europe and handled in accordance with GDPR and local data protection regulations.

“Few problems in healthcare are as large or as overlooked as psychiatry’s, and few founders are as passionate about solving it the way Augusta and Christian are. We’re proud to lead this round, and look forward to supporting them to deliver the next generation of technology for psychiatry,” said Carolin Gabor, Managing Partner and GP at Caesar Ventures. 

The company will use the funding to expand its clinical and engineering teams and enter the UK market. It plans to turn its existing commercial opportunities in private psychiatry into customers ahead of its planned Seed round.